Select Page

PharmaLogic work contributes to glaucoma therapeutics

The American Academy of Ophthalmology recently updated its Glaucoma Practice Pattern. In this document, also published in the AAO’s Journal Ophthalmology, the Committee, headed by Steven J. Gedde, M.D., glaucoma is defined as a chronic, progressive optic neuropathy.  The document then further describes the best practices for diagnosis, follow-up and therapy.  Dr. Novack’s work on the issues of treatment adherence (patients taking their medication as prescribed) and performance (challenges to patients to properly use eyedrops).  His work on novel therapeutics drugs and devices is also cited.

Recent Posts

Gary D. Novack, PhD, president of PharmaLogic Development

Dr. Novack speaking at ASCRS 2014

Dr. Novack talked in two symposia at the Glaucoma 360 event of the Glaucoma Research Foundation in San Francisco.

PharmaLogic sponsor a northern California bicycle riding team “Caballo Rojo

UCSC Chancellor George Blumenthal and Foundation President Ken Doctor thank Dr. Novack for his service to UCSC.

Dr. Novack on floor of California State Assembly with Assemblymember Beall (D-San Jose)

Dr. Novack addresses European Glaucoma Society on Generic Drugs

Dr. Novack with Dr. Wiley Chambers (FDA/CDER), Dr. Ellen Strahlman (CMO GSK), and Dr. Malvina Eydelman (FDA/CDRH) at the Glaucoma 360 event.

Dr. Novack speaking at International Symposium on Ocular Pharmacology and Therapeutics, Vienna, Austria

Dr. Elizabeth Moyer and Dr. Novack at ophthalmology workshop European Medicines Agency

Dr. Novack presents young investigator award at ASPET to Stephanie Piecewicz of MIT